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Larsen scoreAbstract Aim of the work: The aim of this study was to examine vitamin D (VD) levels and its
associations with disease activity, functional disability and radiological damage in Egyptian patients
with RA.
Patients and methods: This study included 150 RA patients and 150 matched controls. All par-
ticipants were not receiving VD supplements. Serum 25(OH)-D levels were measured in all partic-
ipants. Serum 25(OH)-D levels at 30 and 20 ng/ml were the cut-off values for VD insufﬁciency and
deﬁciency, respectively. Associations of 25(OH)-D levels with disease activity score associated with
C-reactive protein (DAS-28-CRP), functional disability assessed by the Health Assessment
Questionnaire (HAQ) and radiological damage as assessed by the modiﬁed Larsen method were
considered.
Results: Low VD levels were frequent in RA patients (22 ± 9.2 ng/ml) compared to the control
(28.7 ± 9.6 ng/ml) (p< 0.001); 42.7% had VD levels <20 ng/ml and was <30 ng/ml in 80.7%. RA
patients with VD deﬁciency were older, more frequently females and had higher swollen joint count
(SJC), tender joint count, visual analogue scale for pain and DAS28-CRP. Only SJC and DAS28-
CRP remained signiﬁcant following the multivariate analysis (p= 0.029, p= 0.007 respectively),
while rheumatoid factor, anti-cyclic citrullinated peptide antibodies, medications used, HAQ and
radiologic score had no association with VD levels.
134 S.R. Elbassiony et al.Conclusions: Vitamin D insufﬁciency and deﬁciency are common among Egyptian RA patients
and are associated with decreased sun exposure. VD deﬁciency was related to older age, female gen-
der, swollen joint count and disease activity. Vitamin D levels had no relation with RA functional
disability and radiological damage.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For the last decade, special attention has been given to the role
of vitamin D (VD) in health and well-being. Vitamin D is a fat-
soluble vitamin that is naturally present in very few foods and
available as a dietary supplement. It is a steroid hormone with
pleiotropic effects. In addition to the main effects of VD on
bone and calcium metabolism it has other roles in the body,
including modulation of cell growth, neuromuscular and
immune function, and reduction of inﬂammation [1]. Many
genes encoding proteins that regulate cell proliferation, differ-
entiation, and apoptosis are modulated in part by VD. Many
cells have VD receptors (VDR), and some convert 25(OH)D
to 1,25(OH)2D. There is a speciﬁc enzyme (CYP27B) that adds
the hydroxyl group to 25(OH)-D to create the 1,25(OH)2-D
(active form) that binds to the nuclear VDR and regulates
the transcription of more than 200 genes. The Immune cell
contains both CYP27B and VDR which means that these cells
are capable of generation of and response to active VD [2].
Monocytes cultured with 1,25(OH)2-D show reduced
expression of MHC class II and co-stimulatory molecules
thereby reducing T cell stimulating capacity [3,4]. The den-
dritic cell capacity is altered by the 1,25(OH)2-D which stimu-
late T cell production and differentiation. Cytokines produced
by dendritic cells shift under the effect of 1,25(OH)2-D by the
inhibition of interleukin (IL)-12, IL-17, IL-23 and interferon-c
with an increase in IL-10 and IL-4 production, resulting in
change of T cell polarization from a T helper (TH)1 and
TH17 response to a TH2 and regulatory T cell predominant
response [5–8]. Absence of inhibition of TH17 response in
VD deﬁciency likely shares the ampliﬁed immune response in
VD deﬁciency.
Vitamin D deﬁciency was reported to be common in RA
patients [9,10] and an association with female sex, disease
severity [9] higher disease activity and worse QoL indices
was suggested [11]. Vitamin D was considered as a good pre-
dictor of RA disease activity in Saudi patients [12]. Other
research studies on the association of VD deﬁciency with RA
provide conﬂicting results. Comparable levels of 25(OH)-D
between RA patients and control were reported in spite of
the presence of an overall high prevalence of VD deﬁciency
in RA [13,14]. In a large cohort of 186,389 women, results
showed absence of signiﬁcant correlation between VD intake
and the incidence of RA [15]. In another study serum levels
of 25(OH)-D were determined in the samples of 79 RA
patients who had donated blood one, two, and ﬁve years
before the onset of symptoms compared to samples from age
and sex matched controls. There was no association between
serum levels of VD and later development of RA [16].
The aim of this cross-sectional study was to examine VD
levels in a group of Egyptians with RA and to identify theassociations between VD insufﬁciency and deﬁciency with dis-
ease activity, functional disability and radiological damage.
2. Patients and methods
The study population included consecutive 150 patients (97
females and 53 males) fulﬁlling the 2010 ACR/EULAR criteria
[17] for classiﬁcation of RA who were attending to outpatient
clinic of Rheumatology and Rehabilitation Department, Man-
soura University Hospital, Egypt and 150 healthy subjects (97
females and 53 males) selected from the general population
who were age and sex matched and were free from any sys-
temic illness to serve as controls. All subjects that participated
in the study were not receiving VD supplements. The study
was conducted between May 2013 and March 2014. An
informed consent was signed by all participants according to
the Declaration of Helsinki. The study was approved by the
local ethics committee.
Patients were subjected to full history taking including cur-
rent and past smoking and to thorough clinical examination
with assessment of the body mass index (BMI). The use of
medications including current and past use of glucocorticoids,
biologic and non-biologic disease modifying anti-rheumatic
drugs (DMARDs), current use of drugs affecting bone meta-
bolism including bisphosphonates, calcium and VD supple-
ments was queried during history taking and reviewed from
the patient’s records. A sun exposure questionnaire was used
to record the amount of sun exposure for each participant
and was expressed as sun exposure index (SEI). The SEI was
deﬁned using the following variables: (1) frequency of outdoor
activity for more than 15 min: daily = 7, 4–6 times a
week = 5, 2–3 times a week = 2.5, once a week = 1, less than
once a week/never = 0; (2) usual time of day of outdoor activ-
ities: between 7 and 11 a.m. = 1, between 11 a.m. and 3 p.m.
= 2, between 3 and 5 p.m. = 1; (3) type of clothing worn out-
doors: long pants, long sleeves, closed shoes, socks and
hat = 0 each, short sleeves, short pants or skirts and open
shoes = 1 each, bathing suit = 2; (4) frequency of sunscreen
use: never = 3, less than 3 times per week = 2, 3–6 times per
week = 1, daily = 0; (5) level of sunscreen protection: no
use = 3, SPF < 15 = 2, SPF 15–30 = 1, SPF > 30 = 0 [18].
At inclusion, the following variables were measured for all
patients: CRP, rheumatoid factor (RF) and anti-cyclic citrulli-
nated peptides antibodies (anti-CCP). Serum calcium, phos-
phorous and alkaline phosphatase were also measured in all
participants.
The RA disease activity was calculated using the Disease
Activity Score for 28 joints with C-reactive protein (DAS28-
CRP) tool [19]. Pain intensity was assessed by a 0–10 visual
analogue scale (VAS-pain) as 0 = no pain; 10 = intense pain.
The 21-item Stanford Health Assessment Questionnaire
Table 1 Characteristics of the rheumatoid arthritis patients and controls.
Variable
Mean ± SD or n (%)
RA patients
(n= 150)
Control
(n= 150)
p
Age (years) 44.2 ± 11.6 46.4 ± 12.9 0.12
BMI 27.6 ± 2.6 27.9 ± 2.7 0.33
SEI 11.9 ± 6.9 13.2 ± 6.5 0.09
Smoking 19 (12.7) 22 (14.7) 0.61
Serum Ca (mg/dl) 9.1 ± 0.6 9.2 ± 0.6 0.15
Serum P (mg/dl) 3.8 ± 0.6 3.9 ± 0.6 0.15
Serum ALP (U/L) 137.8 ± 16.3 135.1 ± 13.1 0.11
Serum 25(OH)-D (ng/ml) 22.0 ± 9.2 28.7 ± 9.6 <0.001
<20 ng/ml 64 (42.7) 34 (22.7)
20–30 ng/ml 57 (38) 45 (30)
>30 ng/ml 29 (19.3) 62 (41.3)
RA duration (months) 23.9 ± 7.1 –
Swollen joint count 13.7 ± 6.9 –
Tender joint count 14.5 ± 6.4 –
VAS-pain 54.7 ± 21 –
CRP (mg/dl) 17.0 ± 7.5 –
RF positivity 102 (68) –
Anti CCP positivity 96 (64) –
Current prednisone 58 (38.7) –
Current DMARDs 130 (86.7) –
Current biologic 48 (32) –
DAS28-CRP 3.8 ± 1.3 –
HAQ 0.61 ± 0.83 –
Larsen radiographic score 24.2 ± 13.8 –
RA: rheumatoid arthritis, BMI: body mass index, SEI: sun exposure index, Ca: calcium, P: phosphorous, ALP: alkaline phosphatase, VAS:
visual analogue scale, CRP: C-reactive protein, RF: rheumatoid factor, CCP: cyclic citrullinated peptide, DMARD: disease modifying anti-
rheumatic drug, DAS-28: disease activity score in 28 joints, HAQ: health assessment questionnaire.
Bold values are signiﬁcant at p< 0.05.
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activities.
In addition, baseline radiographs were obtained to measure
the structural damage of the joints at entry of the study by a
radiologist who was blinded to the clinical and laboratory ﬁnd-
ings. The modiﬁed Larsen method was used to assess the
radiographic damage [21]. The score ranges from 0 to 140.
Vitamin D ‘25(OH)-D’ was studied rather than the more
active form (1,25(OH)2-D), because of its reported stronger
associations with disease activity [22]. 25(OH)-D acts as a sub-
strate for 1,25(OH)2D levels which are also dependent on cal-
cium and phosphorus status in addition to parathyroid
hormone concentrations.
2.1. Determination of serum vitamin D levels
Five ml of venous blood was collected from all patients and
controls by clean venipuncture using plastic disposable syr-
inges. Blood was allowed to clot before centrifugation and
serum was taken. Serum concentrations of 25(OH)-D were
tested using enzyme linked immunosorbent assay (ELISA)
(Cat No. EQ 6411-9601, Euroimmun Medizinische Labordiag-
nostika AG, Germany). Current recommendations deﬁne VD
deﬁciency as serum 25(OH)-D levels less than 20 ng/ml and
VD insufﬁciency less than 30 ng/ml [23].
2.2. Statistical analysis
Continuous variables are presented as mean ± standard devi-
ations (SD). Categorical variables are reported as number andproportions. Data were checked for normality and equality of
distribution, prior to any analysis being performed. Compar-
isons between RA patients and controls were made using inde-
pendent t test for continuous normally distributed variables
while the chi-square test was used for comparison between cat-
egorical variables. The associations of continuous 25(OH)-D
concentrations with measures of disease activity and severity
were ﬁrst examined using univariate regression analyses
(logistic regression for dichotomous outcomes and linear
regression for continuous outcomes) then multivariate regres-
sion analyses were performed. Adjusted odds ratios (OR)
and corresponding 95% conﬁdence intervals (CI) were esti-
mated to ascertain the association of individual factors and
serum VD. All calculations were performed using SPSS 17.0
software for Windows. All analyses were 2-tailed.3. Results
This study included 150 RA patients (97 females and 53 males)
with a mean age of 44.2 ± 11.6 (range; 27–67) years and 150
controls with a mean age of 46.4 ± 12.9 years (range; 25–
66). The characteristics of the patients and control are pre-
sented in Table 1. The disease duration of patients was 23.9
± 7.1 months (95% CI: 22.8–25). The mean DAS-28-CRP
was 3.8 ± 1.3 (95% CI: 3.6–4), HAQ was 0.61 ± 0.83 (95%
CI: 0.48–0.74) and the Larsen score was 24.2 ± 13.8 (95%
CI: 22–26.4). The mean serum VD level was signiﬁcantly
reduced in the RA patients (22 ± 9.2 ng/ml, CI 20.5–23.5)
compared to the control (28.7 ± 9.6 ng/ml, CI 27.1–30.1)
Table 2 Demographic, clinical and laboratory characteristics, disease activity, disability and radiological damage scores in
rheumatoid arthritis patients according to the vitamin D status.
Variable
Mean ± SD or n (%)
RA patients according to the vitamin D status
Deﬁciency
(<20 ng/ml)
(n= 64)
Insuﬃciency
(20–30 ng/ml)
(n= 57)
Normal
(>30 ng/ml)
(n= 29)
Demographic Age (years) 47.4 ± 11.6 42.1 ± 11.3 41.3 ± 10.7
p= 0.013 p= 0.019
DD (years) 23 ± 6.9 24.6 ± 6.9 24.5 ± 6.8
p= 0.2 p= 0.36
Female gender 49 (76.6) 33 (58) 15 (51.7)
p= 0.028 p= 0.019
BMI 27.4 ± 2.4 27.8 ± 2.6 27.5 ± 3
p= 0.4 p= 0.78
SEI 6.5 ± 3.3 12.1 ± 2.1 16.7 ± 1.8
p< 0.001 p< 0.001
Smoking 6 (9.4) 8 (14) 4 (13.8)
p= 0.42 p= 0.52
Clinical SJC 15.4 ± 8.1 12.7 ± 5.7 11.9 ± 5.6
p= 0.04 p= 0.038
TJC 16.2 ± 8.2 13.6 ± 4.7 12.5 ± 3.4
p= 0.034 p= 0.023
VAS-pain 60.5 ± 20.3 52.3 ± 22.5 46.8 ± 16.2
p= 0.036 p= 0.002
Laboratory Serum Ca 9.04 ± 0.7 9.09 ± 0.6 9.13 ± 0.7
p= 0.68 p= 0.57
Serum P 3.79 ± 0.7 3.82 ± 0.7 3.81 ± 0.6
p= 0.81 p= 0.89
Serum ALP 136.7 ± 16.7 138.2 ± 15.3 139.1 ± 15.8
p= 0.6 p= 0.52
RF + ve 44 (68.8) 37 (64.9) 21 (72.4)
p= 0.65 p= 0.72
Anti-CCP+ ve 39 (60.9) 37 (64.9) 22 (75.9)
p= 0.65 p= 0.16
Scores DAS28-CRP 4.1 ± 1.4 3.6 ± 1.3 3.4 ± 1.1
p= 0.023 p= 0.018
HAQ 1.34 ± 0.7 1.15 ± 0.59 1.19 ± 0.64
p= 0.11 p= 0.33
Larsen score 24.7 ± 14.6 24.6 ± 11.9 21.8 ± 13.6
p= 0.48 p= 0.27
DD: disease duration, BMI: body mass index, SEI: sun exposure index, SJC: swollen joint count, TJC: tender joint count, VAS: visual analogue
scale, Ca: calcium, P: phosphorous, ALP: alkaline phosphatase, RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide, DAS-28:
disease activity score in 28 joints, HAQ: health assessment questionnaire. Bold p-values are signiﬁcantly different at p< 0.05 when compared to
values in RA patients with deﬁciency.
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(42.7%) compared to 34 controls (22.7%) had VD deﬁciency
and 57 patients (38%) compared to 45 controls (30%) had
VD insufﬁciency. This difference was statistically signiﬁcant
(p< 0.001) (Table 1).
Demographic, clinical and laboratory characteristics, dis-
ease activity, disability and radiological damage scores in
rheumatoid arthritis patients according to the vitamin D status
are presented in Table 2. Rheumatoid arthritis patients with
VD deﬁciency (n= 64) were compared to those with VD
insufﬁciency (n= 57) and normal VD levels (n= 29) (Table 2).
On comparing the RA patients with VD insufﬁciency to those
with normal VD levels (>30 ng/ml), only the SEI was signiﬁ-
cantly lower (p< 0.001). DAS-28-CRP score was signiﬁcantly
increased in RA patients with VD deﬁciency (4.1 ± 1.4) com-
pared to those with VD insufﬁciency (3.6 ± 1.3) (95% CI,0.07; 1.03, p= 0.023) and to those with normal VD levels
(95% CI, 0.12; 1.28, p= 0.018) (Table 2). The difference
was insigniﬁcant between RA patients with VD insufﬁciency
and normal VD levels (>30 ng/ml). On comparing the medica-
tions received by the RA patients according to their vitamin D
status, no signiﬁcant difference was found (p> 0.05). In the
RA patients with VD deﬁciency (n= 64), 24 (37.5%) were
receiving prednisone, 55 (85.9%) DMARDs and 21 (32.8%)
biologics; in RA patients with VD insufﬁciency (n= 57), 22
(38.6%) were on prednisone, 50 (87.7%) on DMARDs and
19 (33.3%) on biologics while those with normal VD levels
(n= 29), 12 (41.4%) were on prednisone, 25 (86.2%) on
DMARDs and 8 (27.6%) on biologics.
In unadjusted analyses, 25(OH)-D serum levels were inver-
sely associated with SJC (b co-efﬁcient 0.24, p= 0.028), TJC
(b co-efﬁcient 0.31, p= 0.009), VAS-pain (b co-efﬁcient
Table 3 Predictors of serum 25(OH)-D levels in rheumatoid arthritis patients with measures of disease activity, disability and
radiological damage scores as well as rheumatoid factor and anti-CCP as independent risk factors.
Factors Serum 25(OH)-D levels in rheumatoid arthritis patients (n= 150)
Univariate analysis p Multivariate analysis p
95% CI (b /OR) 95% CI (b /OR)
SJC 0.24 (0.45 to 0.03) 0.028 0.301 (0.39 to 0.31) 0.029
TJC 0.31 (0.53 to 0.08) 0.009 0.059 (0.17 to 0.055) 0.31
VAS-pain 0.12 (0.19 to 0.05) 0.001 0.046 (0.05 to 0.15) 0.36
CRP 0.07 (0.13 to 0.27) 0.49 0.15 (0.15 to 0.45) 0.98
DAS28-CRP 1.51 (2.62 to 0.41) 0.008 1.75 (2.29 to 1.21) 0.007
HAQ 1.63 (3.94 to 0.684) 0.17 0.014 (0.03 to 0.004) 0.13
Larsen score 0.004 (0.113 to 0.106) 0.95 0.001 (0.009 to 0.009) 0.98
RF 1.02 (0.98 to 1.06) 0.31 1.03 (0.99 to 1.07) 0.14
Anti-CCP 1.01 (0.98 to 1.05) 0.48 1.03 (0.99 to 1.07) 0.2
SJC: swollen joint count, TJC: tender joint count, VAS: visual analogue scale, CRP: C-reactive protein, DAS-28: disease activity score in 28
joints, HAQ: health assessment questionnaire, RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide. Bold p-values are signiﬁcant
at p< 0.05.
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p= 0.008). There were no associations with CRP serum level,
HAQ, Larsen radiographic score, anti-CCP or RF. The
associations of 25(OH)-D serum levels were only inversely
associated with SJC (b co-efﬁcient 0.301, p= 0.029) and
DAS28-CRP (b co-efﬁcient 1.752, p= 0.007) after multi-
variate adjustments for age and gender (Table 3).
4. Discussion
The current study shows that low VD levels are frequent in RA
patients (42.7% had levels <20 ng/ml and 80.7% had<30 ng/ml)
despite the fact that our population resides in Egypt, a
country with plenty of sunny days. These results are consistent
with several other studies with a reported prevalence of VD
deﬁciency ranging from 30% to 63% among RA patients
[24–30]. In another study on Egyptian RA patients, special
attention was recommended regarding low vitamin D levels.
It was suggested that vitamin D should be corrected and
supplementation considered among the RA management
armamentarium [31], though, some studies have found similar
serum levels of 25(OH)D in RA and control populations
[13,14].
In this study the serum VD in RA patients was signiﬁcantly
lower than that of controls. Similarly, patients with RA
recorded higher rates of VD deﬁciency and insufﬁciency than
controls. However, the proportion of controls with VD deﬁ-
ciency was 22.7% and this proportion rose to 50.2% when
the cut-off point of 30 ng/ml was used which indicates that
VD deﬁciency is a common problem among Egyptians. The
optimal 25(OH)-D concentrations for bone health and extra-
skeletal beneﬁts was reported to range from 36 to 40 ng/ml
[32]. In the present study, only 14 (9.3%) RA patients had
VD serum levels higher than 36 ng/ml, which is comparable
to ﬁndings of Rossini et al. who reported that the optimal
VD concentrations were achieved by 9% of RA patients [30].
In the current study, a signiﬁcant association was observed
between the VD levels and the RA related activity indices.
Speciﬁcally, SJC, TJC, VAS-pain and DAS28-CRP were
signiﬁcantly higher in RA patients with VD deﬁciency ascompared to patients with insufﬁciency or normal VD levels.
Many studies reported inverse signiﬁcant associations between
VD and DAS28 [14,29,30], pain [29], SJC [29] and TJC
[22,30,33] in RA patients.
In agreement with the current results, Kerr et al. found that
serum VD correlated with TJC only in patients with deﬁciency
but not in those with 25(OH)D insufﬁciency [34]. Results
observed in this study as regards the association of VD and
VAS-pain come in agreement with the concept of the associa-
tion between hypovitaminosis D and musculoskeletal pain
[35,36]. Although TJC and VAS-pain were inversely associated
with VD concentration in the univariate analysis, these associ-
ations failed to meet signiﬁcance following multivariate adjust-
ments whereas SJC and DAS28-CRP remained statistically
signiﬁcant following adjustments for age and sex, suggesting
that the association of TJC and VAS-pain is explained primar-
ily by the disease activity.
While these results point towards an association between
VD and disease activity in RA, the results are mixed and there
are many confounding factors. Hypovitaminosis D may not
truly be associated with disease activity in RA, but may reﬂect
poor sun exposure due to decreased mobility of patients with
active RA. The results of the current work revealed that SEI
is signiﬁcantly higher in RA patients with VD insufﬁciency
than in RA patients with SD deﬁciency and is signiﬁcantly
highest in RA patients with VD> 30 ng/ml. This ﬁnding con-
ﬁrms that decreased sun exposure is a risk factor for VD deﬁ-
ciency. The present study revealed that RA patients with VD
deﬁciency are signiﬁcantly older than those with VD insufﬁ-
ciency than those with normal serum VD levels. This may
reﬂect the lower outdoor activity of the older patients com-
pared to those of younger age. Females with RA had a signif-
icantly lower serum VD than males with RA in our study. VD
deﬁciency is a common problem among Egyptian females.
Inadequate sun exposure, possibly related to cultural/social
factors as females in Egypt usually wear clothes that cover
most if not all of their skin, inﬂuence VD levels [37].
In this study, we found no association between VD deﬁ-
ciency and RF, anti-CCP, type of drugs used and the radio-
logic damage score. One study measured serum VD levels in
138 S.R. Elbassiony et al.76 subjects who were either CCP or RF positive but without
clinical evidence of RA. The 25(OH)-D levels in these subjects
who were at high risk of developing RA did not differ from
154 antibody negative controls [38]. In the study of Craig
et al., no association was found between RF, drug use and
radiologic erosions and serum VD levels [29].5. Conclusion
VD insufﬁciency and deﬁciency are common in patients with
RA and are associated with decreased sun exposure. VD deﬁ-
ciency was related to older age, female gender and a higher
degree of RA activity. Only SJC and DAS28-CRP were signif-
icant predictors of VD levels. VD levels had no relation with
functional disability or radiological damage in RA.6. Conflict of interest
None.
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